Chronic Back Pain Pipeline Summary

DelveInsight’s, “Chronic Back Pain - Pipeline Insight, 2026” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Chronic Back Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Chronic Back Pain: Understanding

Chronic Back Pain: Overview

Chronic back pain (CBP) is defined as pain localized to the cervical, thoracic, or lumbar spine that persists for 12 weeks or longer, even after the initial injury or underlying cause has resolved. It is one of the leading causes of disability worldwide and is associated with substantial healthcare utilization, work absenteeism, and reduced quality of life. Chronic back pain may be mechanical (nociceptive), neuropathic, inflammatory, or nociplastic, with common etiologies including degenerative disc disease, facet joint osteoarthritis, spinal stenosis, spondylolisthesis, vertebral fractures, and radiculopathy.

Patients typically present with persistent aching or stiffness, reduced spinal mobility, muscle spasms, radiating leg pain (sciatica), numbness, weakness, and impaired physical function. Psychosocial factors such as anxiety, depression, fear-avoidance behaviors, and sleep disturbances frequently contribute to symptom persistence and disability.

The pathophysiology of chronic back pain is multifactorial and involves peripheral tissue injury, persistent inflammation, nerve sensitization, and maladaptive changes within the central nervous system. Structural abnormalities such as intervertebral disc degeneration, annular fissures, facet arthropathy, ligamentous injury, and nerve root compression may generate nociceptive input, while prolonged pain signaling promotes peripheral and central sensitization, resulting in heightened pain perception.

Neuroimmune interactions, altered pain modulation, and cortical reorganization further contribute to chronic pain, particularly in nociplastic conditions where symptoms may not correlate with structural pathology.

Diagnosis is based primarily on a comprehensive clinical history and physical examination, with evaluation of pain characteristics, neurological deficits, and red flag symptoms. Imaging modalities such as MRI, CT, or radiography are reserved for patients with suspected serious pathology, progressive neurological impairment, or persistent symptoms requiring further evaluation, while laboratory testing is performed when infection, malignancy, or inflammatory disease is suspected.

Management of chronic back pain emphasizes a multimodal, patient-centered approach aimed at improving function and quality of life rather than complete pain elimination. First-line treatment includes structured exercise therapy, physical rehabilitation, patient education, cognitive behavioral therapy (CBT), and self-management strategies, with maintenance of regular physical activity strongly recommended.

Pharmacological options include nonsteroidal anti-inflammatory drugs (NSAIDs) as first-line agents, while duloxetine, selected muscle relaxants, and short-term use of other analgesics may be considered for appropriate patients; routine long-term opioid therapy is generally discouraged because of limited long-term benefit and substantial safety concerns. Interventional procedures such as epidural steroid injections, radiofrequency ablation, spinal cord stimulation, or surgery may be appropriate for carefully selected patients with specific structural abnormalities or refractory pain.

"Chronic Back Pain- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Back Pain pipeline landscape is provided which includes the disease overview and Chronic Back Pain treatment guidelines. The assessment part of the report embraces, in depth Chronic Back Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Back Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Back Pain R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Back Pain.

Chronic Back Pain Emerging Drugs Chapters

This segment of the Chronic Back Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Back Pain Emerging Drugs

CNTX-3001: Centrexion Therapeutics

CNTX-3001 is an investigational non-opioid small-molecule analgesic being developed by Centrexion Therapeutics for the treatment of intractable chronic moderate-to-severe low back pain. The therapy is administered as a single intrathecal injection via lumbar puncture, aiming to provide targeted pain relief while minimizing systemic opioid exposure. It is being evaluated in a first-in-human, randomized, placebo-controlled Phase I trial to assess its safety, tolerability, pharmacokinetics, and preliminary efficacy in patients who have failed multiple prior therapies. According to the company’s pipeline, the drug is in Phase II stage of its development.

LY4065967: Eli Lilly and Company

LY4065967 is an investigational orally administered small-molecule analgesic being developed by Eli Lilly for the treatment of chronic low back pain (CLBP). It is currently being evaluated in a randomized, double-blind, placebo-controlled Phase II trial under Lilly's Chronic Pain Master Protocol (CPMP). The study aims to assess its efficacy in reducing pain intensity, improving physical function, sleep quality, and overall quality of life over an 8-week treatment period in adults with CLBP.

ITX24-01: Interventional AnalgesiX

ITX24-01 is an investigational locally administered analgesic being developed by Interventional AnalgesiX for the treatment of severe chronic facet joint–related neck and lower back pain. It is delivered as a single fluoroscopy-guided medial branch block (MBB) injection and is currently being evaluated in a randomized, double-blind, placebo-controlled Phase Ib dose-escalation study. The trial is designed to assess the safety, tolerability, and preliminary analgesic efficacy of ITX24-01 while evaluating its potential to reduce pain and delay or avoid the need for medial branch radiofrequency neurotomy.

Further product details are provided in the report……..

Chronic Back Pain: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Back Pain drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Chronic Back Pain
• There are approx. 20+ key companies which are developing the therapies for Chronic Back Pain. The companies which have their Chronic Back Pain drug candidates in the mid stage, i.e. Phase II include, Eli Lilly and Company

• Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Chronic Back Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Back Pain: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Chronic Back Pain therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Back Pain drugs.

Chronic Back Pain Report Insights

• Chronic Back Pain Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chronic Back Pain Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chronic Back Pain drugs?
• How many Chronic Back Pain drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Back Pain?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Back Pain therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic Back Pain and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Centrexion Therapeutics
• Eli Lilly and Company
• Interventional AnalgesiX
• Kolon TissueGene, Inc.
• Creative Medical Technology Holdings
• Persica Pharmaceuticals
• BioRestorative Therapies
• Tris Pharma, Inc.
• Contineum Therapeutics
• Mesoblast

Key Products

• CNTX-3001
• LY4065967
• ITX24-01
• TG-C
• CELZ-201-DDT
• PP-353
• BRTX 100
• TRN-228
• PIPE-791
• Rexlemestrocel-L